New antiretroviral drugs, part II: NRTIs, NNRTIs, and beyond.
Murphy
R L
RL
Northwestern University, HIV Treatment Clinic.
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015195:Drug Design; D004352:Drug Resistance, Microbial; D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D006801:Humans; D008561:Membrane Fusion / Q000187:drug effects*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019562:Viral Load
D019380:Anti-HIV Agents; D019428:HIV Integrase Inhibitors; D018894:Reverse Transcriptase Inhibitors